Aeterna Zentaris Announces Election of Directors at its Annual Meeting of Shareholders

About this update from Cosciens Biopharma Inc.

[{"type":"text","content":"\n\n\n\n\n\nQUÉBEC CITY, May 8, 2013 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:\n AEZS) (TSX: AEZ) (the \"Company\") announces the results of the vote on\n directors held earlier today at its annual meeting of shareholders.\n Issuers listed on the Toronto Stock Exchange are required to issue a\n news release providing this information.\n\n\nEach of the director nominees proposed by management for election was\n elected as director, without a vote by ballot being conducted. The\n Company received proxies with regard to voting on the seven directors\n nominated for election as set forth in the table below:\n\n\nName of Nominee\n\n\nVotes For\n\n\n%\n\n\nVotes Withheld\n\n\n%\n\n\nMarcel Aubut\n\n\n2,379,194\n\n\n70.8\n\n\n979,320\n\n\n29.2\n\n\nDavid A. Dodd* \n\n\n2,385,312\n\n\n71.0\n\n\n973,202\n\n\n29.0\n\n\nJosé P. Dorais\n\n\n2,692,560\n\n\n80.2\n\n\n665,954\n\n\n19.8\n\n\nCarolyn Egbert\n\n\n2,351,610\n\n\n70.0\n\n\n1,006,903\n\n\n30.0\n\n\nJuergen Ernst\n\n\n2,339,417\n\n\n69.7\n\n\n1,019,097\n\n\n30.3\n\n\nPierre Lapalme\n\n\n2,375,050\n\n\n70.7\n\n\n982,964\n\n\n29.3\n\n\nGérald Limoges\n\n\n2,380,610\n\n\n70.9\n\n\n977,404\n\n\n29.1\n\n\n(*)  \n\n\nThe results for the proxies received regarding Mr. Dodd were originally\n received for the Company's former President and Chief Executive Officer\n and director, Prof. Juergen Engel. As announced by the Company on April\n 15, 2013, Mr. Dodd succeeded to Prof. Engel as President and Chief\n Executive Officer, and Mr. Dodd was also concurrently appointed to the\n Board of Directors. At the same time, the Company announced that\n Mr. Dodd would be one of the management director nominees for election\n at the Company's annual meeting of shareholders and that Management\n proxy holders intended to exercise the discretion granted in the\n proxies to vote in favour of the election of Mr. Dodd as a director at\n the shareholders' meeting.\n\n\n\n\n\nAll other matters at the shareholders' meeting, namely the renewal of\n and amendment to the Company's Stock Option Plan, the reconfirmation\n and approval of the Shareholder Rights Plan and the confirmation of an\n amendment to the Company's bylaws, were also approved by shareholders.\n\n\nAbout Aeterna Zentaris \n\n\nAeterna Zentaris is an oncology and endocrinology drug development\n...

More updates from Cosciens Biopharma Inc.